AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
AL Amyloidosis, POEMS Syndrome, and Extramedullary Myeloma: Diagnosis Lags, Treatment Options Grow
By Jack Khouri, MD
AL amyloidosis remains a frequently missed, "sneaky" diagnosis, but the treatment landscape is genuinely transforming
AL Amyloidosis, POEMS Syndrome, and Extramedullary Myeloma: Diagnosis Lags, Treatment Options Grow
By Jack Khouri, MD
AL amyloidosis remains a frequently missed, "sneaky" diagnosis, but the treatment landscape is genuinely transforming
AL Amyloidosis, POEMS Syndrome, and Extramedullary Myeloma: Diagnosis Lags, Treatment Options Grow
By Jack Khouri, MD
AL amyloidosis remains a frequently missed, "sneaky" diagnosis, but the treatment landscape is genuinely transforming
Early-Stage Breast Cancer: Why Fewer Patients Need Chemotherapy, and More Need CDK4/6 Inhibitors
By Ruta Rao, MD
Genomic testing is increasingly identifying which early-stage, hormone receptor-positive breast cancer patients can safely skip chemotherapy, even among some node-positive premenopausal women.
Early-Stage Breast Cancer: Why Fewer Patients Need Chemotherapy, and More Need CDK4/6 Inhibitors
By Ruta Rao, MD
Genomic testing is increasingly identifying which early-stage, hormone receptor-positive breast cancer patients can safely skip chemotherapy, even among some node-positive premenopausal women.
Early-Stage Breast Cancer: Why Fewer Patients Need Chemotherapy, and More Need CDK4/6 Inhibitors
By Ruta Rao, MD
Genomic testing is increasingly identifying which early-stage, hormone receptor-positive breast cancer patients can safely skip chemotherapy, even among some node-positive premenopausal women.
Beyond G12C: KRAS Lung Cancer Is About to Become a Toolkit, Not a Single Target
By Benjamin Herzberg, MD
KRAS G12C is not the only KRAS mutation worth worrying about, and I think that idea is very close to being obsolete.
Beyond G12C: KRAS Lung Cancer Is About to Become a Toolkit, Not a Single Target
By Benjamin Herzberg, MD
KRAS G12C is not the only KRAS mutation worth worrying about, and I think that idea is very close to being obsolete.
Beyond G12C: KRAS Lung Cancer Is About to Become a Toolkit, Not a Single Target
By Benjamin Herzberg, MD
KRAS G12C is not the only KRAS mutation worth worrying about, and I think that idea is very close to being obsolete.
Head and Neck Cancer: New Antibodies After Checkpoint Failure, and Rethinking Immunotherapy Plus Radiation
By Weining Ken Zhen, MD
Developing new strategies for advanced head and neck cancer after checkpoint inhibitor and chemotherapy failures.
Head and Neck Cancer: New Antibodies After Checkpoint Failure, and Rethinking Immunotherapy Plus Radiation
By Weining Ken Zhen, MD
Developing new strategies for advanced head and neck cancer after checkpoint inhibitor and chemotherapy failures.
Head and Neck Cancer: New Antibodies After Checkpoint Failure, and Rethinking Immunotherapy Plus Radiation
By Weining Ken Zhen, MD
Developing new strategies for advanced head and neck cancer after checkpoint inhibitor and chemotherapy failures.
Colorectal Cancer: Exercise Pays Off, Aspirin's Role Stays Murky, Some Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Colorectal Cancer: Exercise Pays Off, Aspirin's Role Stays Murky, Some Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Colorectal Cancer: Exercise Pays Off, Aspirin's Role Stays Murky, Some Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Kidney Cancer: Conflicting Adjuvant Immunotherapy Data and a Real Option for Non-Clear Cell Disease
By Benjamin A. Teply, MD
We have yet to have truly confirmatory data for a benefit for adjuvant immunotherapy in kidney cancer.
Kidney Cancer: Conflicting Adjuvant Immunotherapy Data and a Real Option for Non-Clear Cell Disease
By Benjamin A. Teply, MD
We have yet to have truly confirmatory data for a benefit for adjuvant immunotherapy in kidney cancer.
Kidney Cancer: Conflicting Adjuvant Immunotherapy Data and a Real Option for Non-Clear Cell Disease
By Benjamin A. Teply, MD
We have yet to have truly confirmatory data for a benefit for adjuvant immunotherapy in kidney cancer.
Rethinking Frontline Therapy in Leukemia: Why Lower-Intensity Regimens Are Gaining Ground in AML, MDS, and ALL
By Anand Ashwin Patel, MD
Newer data are steadily narrowing the population that benefits from intensive chemotherapy in acute leukemia.
Rethinking Frontline Therapy in Leukemia: Why Lower-Intensity Regimens Are Gaining Ground in AML, MDS, and ALL
By Anand Ashwin Patel, MD
Newer data are steadily narrowing the population that benefits from intensive chemotherapy in acute leukemia.
Rethinking Frontline Therapy in Leukemia: Why Lower-Intensity Regimens Are Gaining Ground in AML, MDS, and ALL
By Anand Ashwin Patel, MD
Newer data are steadily narrowing the population that benefits from intensive chemotherapy in acute leukemia.
Gastrointestinal Cancer Updates From the Best of GI Oncology 2026
By Haadi Ali, MD ; Ibrahim Halil Sahin, MD
Daraxonrasib is an orally administered, multiselective RAS(ON) inhibitor designed to target the active, GTP-bound state of multiple mutant and wild-type RAS proteins.
Gastrointestinal Cancer Updates From the Best of GI Oncology 2026
By Haadi Ali, MD ; Ibrahim Halil Sahin, MD
Daraxonrasib is an orally administered, multiselective RAS(ON) inhibitor designed to target the active, GTP-bound state of multiple mutant and wild-type RAS proteins.
Gastrointestinal Cancer Updates From the Best of GI Oncology 2026
By Haadi Ali, MD ; Ibrahim Halil Sahin, MD
Daraxonrasib is an orally administered, multiselective RAS(ON) inhibitor designed to target the active, GTP-bound state of multiple mutant and wild-type RAS proteins.
Tarlatamab for Small Cell Lung Cancer: How DLL3-Targeted Therapy Works
By Daniel Ricardo Carrizosa, MD, MS
Small cell lung cancer has long been considered one of the more difficult diagnoses in thoracic oncology.
Tarlatamab for Small Cell Lung Cancer: How DLL3-Targeted Therapy Works
By Daniel Ricardo Carrizosa, MD, MS
Small cell lung cancer has long been considered one of the more difficult diagnoses in thoracic oncology.
Tarlatamab for Small Cell Lung Cancer: How DLL3-Targeted Therapy Works
By Daniel Ricardo Carrizosa, MD, MS
Small cell lung cancer has long been considered one of the more difficult diagnoses in thoracic oncology.
A New Antibody-Drug Conjugate and a Biomarker Reality Check for Small Cell Lung Cancer
By Mark Alan Klein, MD
Small cell lung cancer has trailed its non-small cell counterpart in new drug approvals for years, and at this year's ASCO meeting there were no studies presented that affect first-line treatments at this time.
A New Antibody-Drug Conjugate and a Biomarker Reality Check for Small Cell Lung Cancer
By Mark Alan Klein, MD
Small cell lung cancer has trailed its non-small cell counterpart in new drug approvals for years, and at this year's ASCO meeting there were no studies presented that affect first-line treatments at this time.
A New Antibody-Drug Conjugate and a Biomarker Reality Check for Small Cell Lung Cancer
By Mark Alan Klein, MD
Small cell lung cancer has trailed its non-small cell counterpart in new drug approvals for years, and at this year's ASCO meeting there were no studies presented that affect first-line treatments at this time.